Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE III RANDOMIZED TRIAL OF FOLFOXIRI + BEVACIZUMAB VERSUS FOLFIRI + BEVACIZUMAB AS FIRST- LINE TREATMENT FOR METASTATIC COLORECTAL CANCER

Trial Profile

A PHASE III RANDOMIZED TRIAL OF FOLFOXIRI + BEVACIZUMAB VERSUS FOLFIRI + BEVACIZUMAB AS FIRST- LINE TREATMENT FOR METASTATIC COLORECTAL CANCER

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms TRIBE
  • Most Recent Events

    • 05 Jun 2018 Results of FOLFOXIRI plus Bevacizumab for tumor sidedness and benefit were presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2018 Results of a genome-wide association study (GWAS) of overall survival (OS) and progression-free survival (PFS) in 790 patients from 3 clinical trials (FIRE-3, TRIBE, and MAVERICC), presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 05 Jun 2018 Results (n=451) assessing the polymorphism in the circadian clock pathway for prediction of outcome in patients with metastatic colorectal cancer using genomic DNA from blood samples of patients from TRIBE and FIRE-3 phase III trials, presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top